[Source: Journal of Antimicrobial Chemotherapy, full page: (LINK). Summary, edited.]
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection
Evelyn Shaw, Alexander Rombauts, Fe Tubau, Ariadna Padullés, Jordi Càmara, Toni Lozano, Sara Cobo-Sacristán, Núria Sabe, Imma Grau, Raül Rigo-Bonnin, M Angeles Dominguez, Jordi Carratalà
Journal of Antimicrobial Chemotherapy, dkx496, https://doi.org/10.1093/jac/dkx496
Published: 19 December 2017
The growing spread of bacteria producing carbapenemases, such as the New Delhi MBL (NDM),1 has created an urgent need to identify effective therapeutic options that can treat serious infections caused by these XDR bacteria. Ceftazidime/avibactam has been successfully used to treat infection caused by carbapenem-resistant Enterobacteriaceae;2,3 however, the combination lacks activity against strains producing NDM. These carbapenemases remain susceptible to aztreonam, although most MBL-producing isolates also harbour ESBLs or other β-lactamases that confer resistance to aztreonam.4 The combination of aztreonam and avibactam has demonstrated potent in vitroactivity against MBL-producing Enterobacteriaceae including those isolates that also carry other β-lactamases.5 However, this combination is currently in clinical development and unavailable for clinical use.
Issue Section: Research letter
© The Author(s) 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: email@example.com.
Keywords: Antibiotics; Drugs Resistance; Klebsiella Pneumoniae; NDM1; Ceftazidime; Avibactam; Aztreonam.